Previous trials showed that chemotherapy could provide an ORR of 27%–42.9%, with a mPFS of 4.4–5.6 months for these EGFR-TKI resistant NSCLC patients (Liam et al., 2023; Soria et al., 2015; Yang et al., 2024). This evidence concerns the gene EGFR and non-small cell lung carcinoma.